Evolving concepts on the role of dyslipidemia, bioenergetics, and inflammation in the pathogenesis and treatment of diabetic peripheral neuropathy

Diabetic peripheral neuropathy (DPN) is one of the most widespread and disabling neurological conditions, accounting for half of all neuropathy cases worldwide. Despite its high prevalence, no approved disease modifying therapies exist. There is now a growing body of evidence that DPN secondary to type 1 diabetes mellitus (T1DM) and type 2 diabetes mellitus (T2DM) represents different disease processes, with T2DM DPN best understood within the context of metabolic syndrome rather than hyperglycemia. In this review, we highlight currently understood mechanisms of DPN, along with their corresponding potential therapeutic targets. We frame this discussion within a practical overview of how the field evolved from initial human observations to murine pathomechanistic and therapeutic models into ongoing and human clinical trials, with particular emphasis on T2DM DPN and metabolic syndrome.

[1]  E. Feldman,et al.  The emerging role of dyslipidemia in diabetic microvascular complications. , 2020, Current opinion in endocrinology, diabetes, and obesity.

[2]  J. Hur,et al.  Toll-like receptors and inflammation in metabolic neuropathy; a role in early versus late disease? , 2019, Experimental Neurology.

[3]  P. Fort,et al.  New insights into the mechanisms of diabetic complications: role of lipids and lipid metabolism , 2019, Diabetologia.

[4]  E. Feldman,et al.  The Divergent Roles of Dietary Saturated and Monounsaturated Fatty Acids on Nerve Function in Murine Models of Obesity , 2019, The Journal of Neuroscience.

[5]  S. Garg,et al.  Association of Statin Therapy With Prevention of Vision-Threatening Diabetic Retinopathy , 2019, JAMA ophthalmology.

[6]  Junguk Hur,et al.  Pathway crosstalk perturbation network modeling for identification of connectivity changes induced by diabetic neuropathy and pioglitazone , 2019, BMC Systems Biology.

[7]  S. Eid,et al.  Integrated lipidomic and transcriptomic analyses identify altered nerve triglycerides in mouse models of prediabetes and type 2 diabetes , 2019, Disease Models & Mechanisms.

[8]  W. Rathmann,et al.  General and Abdominal Obesity and Incident Distal Sensorimotor Polyneuropathy: Insights Into Inflammatory Biomarkers as Potential Mediators in the KORA F4/FF4 Cohort , 2018, Diabetes Care.

[9]  Brett A. McGregor,et al.  Conserved Transcriptional Signatures in Human and Murine Diabetic Peripheral Neuropathy , 2018, Scientific Reports.

[10]  E. Feldman,et al.  Chain length of saturated fatty acids regulates mitochondrial trafficking and function in sensory neurons , 2018, Journal of Lipid Research.

[11]  J. Hur,et al.  Transcriptional networks of progressive diabetic peripheral neuropathy in the db/db mouse model of type 2 diabetes: An inflammatory story , 2018, Experimental Neurology.

[12]  M. Banerjee,et al.  Diabetes and obesity are the main metabolic drivers of peripheral neuropathy , 2018, Annals of clinical and translational neurology.

[13]  E. Feldman,et al.  Juvenile murine models of prediabetes and type 2 diabetes develop neuropathy , 2018, Disease Models & Mechanisms.

[14]  E. Feldman,et al.  Dyslipidemia impairs mitochondrial trafficking and function in sensory neurons , 2018, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[15]  A. Boulton,et al.  Diagnostic utility of corneal confocal microscopy and intra-epidermal nerve fibre density in diabetic neuropathy , 2017, PloS one.

[16]  T. Wolever,et al.  Effect of omega-3 supplementation on neuropathy in type 1 diabetes , 2017, Neurology.

[17]  E. Feldman,et al.  Dietary reversal of neuropathy in a murine model of prediabetes and metabolic syndrome , 2017, Disease Models & Mechanisms.

[18]  R. Kardon,et al.  Early vs. late intervention of high fat/low dose streptozotocin treated C57Bl/6J mice with enalapril, α-lipoic acid, menhaden oil or their combination: Effect on diabetic neuropathy related endpoints , 2017, Neuropharmacology.

[19]  G. Bray,et al.  Effects of a long-term lifestyle modification programme on peripheral neuropathy in overweight or obese adults with type 2 diabetes: the Look AHEAD study , 2017, Diabetologia.

[20]  Felix Eichinger,et al.  Comparative RNA‐Seq transcriptome analyses reveal distinct metabolic pathways in diabetic nerve and kidney disease , 2017, Journal of cellular and molecular medicine.

[21]  M. Banerjee,et al.  Association Between Metabolic Syndrome Components and Polyneuropathy in an Obese Population. , 2016, JAMA neurology.

[22]  J. W. Neck,et al.  Systematic review of treatments for diabetic peripheral neuropathy , 2016, Diabetic medicine : a journal of the British Diabetic Association.

[23]  R. Lamuela-Raventós,et al.  Dietary Marine ω-3 Fatty Acids and Incident Sight-Threatening Retinopathy in Middle-Aged and Older Individuals With Type 2 Diabetes: Prospective Investigation From the PREDIMED Trial. , 2016, JAMA ophthalmology.

[24]  O. Franco,et al.  Metabolic syndrome is related to polyneuropathy and impaired peripheral nerve function: a prospective population-based cohort study , 2016, Journal of Neurology, Neurosurgery & Psychiatry.

[25]  M. Pasnoor,et al.  Activity for Diabetic Polyneuropathy (ADAPT): Study Design and Protocol for a 2‐Site Randomized Controlled Trial , 2016, Physical therapy.

[26]  E. Kang,et al.  Effects of Omega-3 Fatty Acid Supplementation on Diabetic Nephropathy Progression in Patients with Diabetes and Hypertriglyceridemia , 2016, PloS one.

[27]  M. Banerjee,et al.  Metabolic Syndrome Components Are Associated With Symptomatic Polyneuropathy Independent of Glycemic Status , 2016, Diabetes Care.

[28]  Lei Zhang,et al.  Dietary fish oil inhibits mechanical allodynia and thermal hyperalgesia in diabetic rats by blocking nuclear factor-κB-mediated inflammatory pathways. , 2015, The Journal of nutritional biochemistry.

[29]  R. Dobrowsky,et al.  Modulating Molecular Chaperones Improves Mitochondrial Bioenergetics and Decreases the Inflammatory Transcriptome in Diabetic Sensory Neurons. , 2015, ACS chemical neuroscience.

[30]  P. Fernyhough.  Mitochondrial Dysfunction in Diabetic Neuropathy: a Series of Unfortunate Metabolic Events , 2015, Current Diabetes Reports.

[31]  Randy H Kardon,et al.  Effect of enriching the diet with menhaden oil or daily treatment with resolvin D1 on neuropathy in a mouse model of type 2 diabetes. , 2015, Journal of neurophysiology.

[32]  M. Kretzler,et al.  The Metabolic Syndrome and Microvascular Complications in a Murine Model of Type 2 Diabetes , 2015, Diabetes.

[33]  Minshan Jiang,et al.  Corneal confocal microscopy for assessment of diabetic peripheral neuropathy: a meta-analysis , 2015, British Journal of Ophthalmology.

[34]  B. Zinman,et al.  Peripheral Neuropathy and Nerve Dysfunction in Individuals at High Risk for Type 2 Diabetes: The PROMISE Cohort , 2015, Diabetes Care.

[35]  J. Mann,et al.  Pathways of polyunsaturated fatty acid utilization: Implications for brain function in neuropsychiatric health and disease , 2015, Brain Research.

[36]  J. Hur,et al.  BTBR ob/ob mice as a novel diabetic neuropathy model: Neurological characterization and gene expression analyses , 2015, Neurobiology of Disease.

[37]  R. Marcus,et al.  Supervised exercise improves cutaneous reinnervation capacity in metabolic syndrome patients , 2015, Annals of neurology.

[38]  J. Groves,et al.  Peroxynitrite and protein nitration in the pathogenesis of diabetic peripheral neuropathy , 2014, Diabetes/metabolism research and reviews.

[39]  E. Feldman,et al.  Hyperglycemia- and neuropathy-induced changes in mitochondria within sensory nerves , 2014, Annals of clinical and translational neurology.

[40]  R. Lloyd,et al.  The roles of the epithelial-mesenchymal transition marker PRRX1 and miR-146b-5p in papillary thyroid carcinoma progression. , 2014, The American journal of pathology.

[41]  Han-Kyu Lee,et al.  Oleate prevents palmitate-induced mitochondrial dysfunction, insulin resistance and inflammatory signaling in neuronal cells. , 2014, Biochimica et biophysica acta.

[42]  P. Krishan,et al.  Minocycline improves peripheral and autonomic neuropathy in type 2 diabetes: MIND study , 2014, Neurological Sciences.

[43]  R. Dobrowsky,et al.  Heat Shock Protein 70 Is Necessary to Improve Mitochondrial Bioenergetics and Reverse Diabetic Sensory Neuropathy following KU-32 Therapy , 2014, The Journal of Pharmacology and Experimental Therapeutics.

[44]  Keivan Basiri,et al.  The effects of intradermal botulinum toxin type a injections on pain symptoms of patients with diabetic neuropathy , 2014, Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences.

[45]  M. Owen,et al.  Mathematical modelling of cytokine-mediated inflammation in rheumatoid arthritis. , 2013, Mathematical medicine and biology : a journal of the IMA.

[46]  H. Kenngott,et al.  Gastric Bypass Leads to Improvement of Diabetic Neuropathy Independent of Glucose Normalization—Results of a Prospective Cohort Study (DiaSurg 1 Study) , 2013, Annals of surgery.

[47]  K. Lovell,et al.  An exploration of the follow-up up needs of patients with inflammatory bowel disease. , 2013, Journal of Crohn's & colitis.

[48]  P. Schestatsky,et al.  Disturbed sensory perception of changes in thermoalgesic stimuli in patients with small fiber neuropathies , 2013, PAIN®.

[49]  J. Singleton,et al.  Obesity and hyperlipidemia are risk factors for early diabetic neuropathy. , 2013, Journal of diabetes and its complications.

[50]  Linuo Zhou,et al.  Determination of Peripheral Neuropathy Prevalence and Associated Factors in Chinese Subjects with Diabetes and Pre-Diabetes – ShangHai Diabetic neuRopathy Epidemiology and Molecular Genetics Study (SH-DREAMS) , 2013, PloS one.

[51]  Wei-Ta Chen,et al.  OnabotulinumtoxinA Improves Tactile and Mechanical Pain Perception in Painful Diabetic Polyneuropathy , 2013, The Clinical journal of pain.

[52]  J. Milbrandt,et al.  Aberrant Schwann Cell Lipid Metabolism Linked to Mitochondrial Deficits Leads to Axon Degeneration and Neuropathy , 2013, Neuron.

[53]  P. Fernyhough,et al.  The role of aberrant mitochondrial bioenergetics in diabetic neuropathy , 2013, Neurobiology of Disease.

[54]  H. Franssen,et al.  Temperature threshold testing: a systematic review , 2013, Journal of the peripheral nervous system : JPNS.

[55]  Nathan Efron,et al.  Corneal Confocal Microscopy Detects Early Nerve Regeneration in Diabetic Neuropathy After Simultaneous Pancreas and Kidney Transplantation , 2012, Diabetes.

[56]  P. Wiffen.  ENHANCED GLUCOSE CONTROL FOR PREVENTING AND TREATING DIABETIC NEUROPATHY , 2012 .

[57]  J. Hur,et al.  Diabetic neuropathy: one disease or two? , 2012, Current opinion in neurology.

[58]  Neena K Sharma,et al.  The effect of exercise on neuropathic symptoms, nerve function, and cutaneous innervation in people with diabetic peripheral neuropathy. , 2012, Journal of diabetes and its complications.

[59]  Á. Soriano,et al.  Mitochondrial loss indicates early axonal damage in small fiber neuropathies , 2012, Journal of the peripheral nervous system : JPNS.

[60]  N. Hasanova,et al.  Triglyceride, nonesterified fatty acids, and prediabetic neuropathy: role for oxidative-nitrosative stress. , 2012, Free radical biology & medicine.

[61]  L. Diep,et al.  The Effects of Long-Term Oral Benfotiamine Supplementation on Peripheral Nerve Function and Inflammatory Markers in Patients With Type 1 Diabetes , 2012, Diabetes Care.

[62]  G. Cavaletti,et al.  Diabetes-induced myelin abnormalities are associated with an altered lipid pattern: protective effects of LXR activation[S] , 2012, Journal of Lipid Research.

[63]  C. Leyton,et al.  Thermal Threshold: Research Study on Small Fiber Dysfunction in Distal Diabetic Polyneuropathy , 2012, Journal of diabetes science and technology.

[64]  H. V. Jagadish,et al.  The identification of gene expression profiles associated with progression of human diabetic neuropathy. , 2011, Brain : a journal of neurology.

[65]  E. Feldman,et al.  Diabetic neuropathy: cellular mechanisms as therapeutic targets , 2011, Nature Reviews Neurology.

[66]  S. Nawfar,et al.  Effects of monochromatic infrared energy therapy on diabetic feet with peripheral sensory neuropathy: a randomised controlled trial. , 2011, Singapore medical journal.

[67]  M. Kretzler,et al.  Transcriptional Profiling of Diabetic Neuropathy in the BKS db/db Mouse , 2011, Diabetes.

[68]  Jennifer Y. Liu,et al.  Triglycerides and Amputation Risk in Patients With Diabetes , 2011, Diabetes Care.

[69]  Chung-Soo Lee,et al.  7-Ketocholesterol induces apoptosis in differentiated PC12 cells via reactive oxygen species-dependent activation of NF-κB and Akt pathways , 2011, Neurochemistry International.

[70]  M. Nangle,et al.  Effects of interleukin‐6 treatment on neurovascular function, nerve perfusion and vascular endothelium in diabetic rats , 2010, Diabetes, obesity & metabolism.

[71]  H. Gullu,et al.  Gabapentin therapy improves heart rate variability in diabetic patients with peripheral neuropathy. , 2010, Journal of diabetes and its complications.

[72]  Nathan Efron,et al.  Corneal Confocal Microscopy , 2010, Diabetes Care.

[73]  M. Nowicki,et al.  Oxidized low‐density lipoprotein (oxLDL)‐induced cell death in dorsal root gangion cell cultures depends not on the lectin‐like oxLDL receptor‐1 but on the toll‐like receptor‐4 , 2010, Journal of neuroscience research.

[74]  A. Boulton,et al.  Effect of l‐arginine on the microcirculation in the neuropathic diabetic foot in Type 2 diabetes mellitus: a double‐blind, placebo‐controlled study , 2010, Diabetic medicine : a journal of the British Diabetic Association.

[75]  R. Danis,et al.  Ruboxistaurin: PKC-β inhibition for complications of diabetes , 2009, Expert opinion on pharmacotherapy.

[76]  R. Goldberg.  Cytokine and cytokine-like inflammation markers, endothelial dysfunction, and imbalanced coagulation in development of diabetes and its complications. , 2009, The Journal of clinical endocrinology and metabolism.

[77]  E. Feldman,et al.  Dyslipidemia-Induced Neuropathy in Mice , 2009, Diabetes.

[78]  L. Markó,et al.  Effects of pentoxifylline and pentosan polysulphate combination therapy on diabetic neuropathy in type 2 diabetes mellitus , 2009, Acta Diabetologica.

[79]  I. Strokov,et al.  Treatment of Symptomatic Polyneuropathy With Actovegin in Type 2 Diabetic Patients , 2009, Diabetes Care.

[80]  M. Laakso,et al.  Effect of fenofibrate on amputation events in people with type 2 diabetes mellitus (FIELD study): a prespecified analysis of a randomised controlled trial , 2009, The Lancet.

[81]  E. Feldman,et al.  Elevated Triglycerides Correlate With Progression of Diabetic Neuropathy , 2009, Diabetes.

[82]  R. Buchanan,et al.  Ranirestat for the Management of Diabetic Sensorimotor Polyneuropathy , 2009, Diabetes Care.

[83]  W. Rathmann,et al.  Neuropathic pain in diabetes, prediabetes and normal glucose tolerance: the MONICA/KORA Augsburg Surveys S2 and S3. , 2009, Pain medicine.

[84]  J. Ansquer,et al.  Fibrates and microvascular complications in diabetes--insight from the FIELD study. , 2009, Current pharmaceutical design.

[85]  E. Evans,et al.  Role of Acetyl-L-Carnitine in the Treatment of Diabetic Peripheral Neuropathy , 2008, The Annals of pharmacotherapy.

[86]  M. A. Ramirez,et al.  Epalrestat: An Aldose Reductase Inhibitor for the Treatment of Diabetic Neuropathy , 2008, Pharmacotherapy.

[87]  K. Ekberg,et al.  Effect of C-Peptide on Diabetic Neuropathy in Patients with Type 1 Diabetes , 2008, Experimental diabetes research.

[88]  B. Yeap,et al.  Lipid-lowering therapy and peripheral sensory neuropathy in type 2 diabetes: the Fremantle Diabetes Study , 2008, Diabetologia.

[89]  R. Pop-Busui,et al.  Protective Effects of Cyclooxygenase-2 Gene Inactivation Against Peripheral Nerve Dysfunction and Intraepidermal Nerve Fiber Loss in Experimental Diabetes , 2007, Diabetes.

[90]  A. Sastry,et al.  Receptor for advanced glycation end products activation injures primary sensory neurons via oxidative stress. , 2007, Endocrinology.

[91]  U. Munzel,et al.  Oral Treatment With α-Lipoic Acid Improves Symptomatic Diabetic Polyneuropathy , 2006, Diabetes Care.

[92]  T. Harrison.  Faculty Opinions recommendation of Lifestyle intervention for pre-diabetic neuropathy. , 2006 .

[93]  A. Goldfine,et al.  Inflammation and insulin resistance. , 2006, The Journal of clinical investigation.

[94]  R. Kawamori,et al.  Long-Term Clinical Effects of Epalrestat, an Aldose Reductase Inhibitor, on Diabetic Peripheral Neuropathy , 2006, Diabetes Care.

[95]  N. Callizot,et al.  Interleukin‐6 attenuates the development of experimental diabetes‐related neuropathy , 2006, Neuropathology : official journal of the Japanese Society of Neuropathology.

[96]  F. Leonetti,et al.  Exercise training can modify the natural history of diabetic peripheral neuropathy. , 2005, Journal of diabetes and its complications.

[97]  R. Hughes,et al.  A controlled investigation of the cause of chronic idiopathic axonal polyneuropathy. , 2004, Brain : a journal of neurology.

[98]  Justin C McArthur,et al.  The time course of epidermal nerve fibre regeneration: studies in normal controls and in people with diabetes, with and without neuropathy. , 2004, Brain : a journal of neurology.

[99]  P. O'Brien,et al.  The Sensory Symptoms of Diabetic Polyneuropathy Are Improved With α-Lipoic Acid , 2003 .

[100]  C. Sumner,et al.  The spectrum of neuropathy in diabetes and impaired glucose tolerance , 2003, Neurology.

[101]  K. Yuen,et al.  Treatment of chronic painful diabetic neuropathy with isosorbide dinitrate spray: a double-blind placebo-controlled cross-over study. , 2002, Diabetes care.

[102]  P. Libby,et al.  Inflammation and Atherosclerosis , 2002, Circulation.

[103]  Stuart K. Calderwood,et al.  HSP70 stimulates cytokine production through a CD14-dependant pathway, demonstrating its dual role as a chaperone and cytokine , 2000, Nature Medicine.

[104]  H. Tritschler,et al.  Effects of 3‐week oral treatment with the antioxidant thioctic acid (α‐lipoic acid) in symptomatic diabetic polyneuropathy , 1999, Diabetic medicine : a journal of the British Diabetic Association.

[105]  M. Hanefeld,et al.  Treatment of symptomatic diabetic polyneuropathy with the antioxidant alpha-lipoic acid: a 7-month multicenter randomized controlled trial (ALADIN III Study). ALADIN III Study Group. Alpha-Lipoic Acid in Diabetic Neuropathy. , 1999, Diabetes care.

[106]  J. Riggs.  Recombinant human nerve growth factor in the treatment of diabetic polyneuropathy. , 1998, Neurology.

[107]  W. Litchy,et al.  Recombinant human nerve growth factor in the treatment of diabetic polyneuropathy , 1998, Neurology.

[108]  B. Bravenboer,et al.  Treatment of diabetic polyneuropathy with the neurotrophic peptide ORG 2766 , 1996, Journal of Neurology.

[109]  M. Hanefeld,et al.  Treatment of symptomatic diabetic peripheral neuropathy with the anti-oxidant alpha-lipoic acid. A 3-week multicentre randomized controlled trial (ALADIN Study). , 1995, Diabetologia.

[110]  A. Barnett,et al.  Clinical and Neurophysiological Studies of Aldose Reductase Inhibitor Ponalrestat in Chronic Symptomatic Diabetic Peripheral Neuropathy , 1991, Diabetes.

[111]  E. Feldman,et al.  Disorders of mitochondrial dynamics in peripheral neuropathy: Clues from hereditary neuropathy and diabetes. , 2019, International review of neurobiology.

[112]  E. Feldman,et al.  Diabetic neuropathy. , 2019, Nature reviews. Disease primers.

[113]  E. Feldman,et al.  Mouse models of diabetic neuropathy. , 2014, ILAR journal.

[114]  M. Cotter,et al.  Pro-inflammatory mechanisms in diabetic neuropathy: focus on the nuclear factor kappa B pathway. , 2008, Current drug targets.

[115]  V. Ia,et al.  [Effect of alpha-lipoic acid and mexidol on neuro- and the affective status in patients at early stages of diabetic foot syndrome]. , 2008 .

[116]  M. N. Alekseev,et al.  [Effect of alpha-lipoic acid and mexidol on neuro- and the affective status in patients at early stages of diabetic foot syndrome]. , 2008, Klinicheskaia meditsina.

[117]  P. O'Brien,et al.  The sensory symptoms of diabetic polyneuropathy are improved with alpha-lipoic acid: the SYDNEY trial. , 2003, Diabetes care.

[118]  S. Apfel.  Nerve growth factor for the treatment of diabetic neuropathy: what went wrong, what went right, and what does the future hold? , 2002, International review of neurobiology.